#USA #Boston #Prostate Cancer #Blue Earth Diagnostics #POSLUMA

Blue Earth Diagnostics Presents Findings on POSLUMA

Blue Earth Diagnostics, a subsidiary of Bracco and a prominent figure in the realm of positron emission tomography (PET) radiopharmaceuticals, has made headlines with their latest study results concerning prostate cancer. Conducted as the first in-depth head-to-head evaluation of urinary bladder radioactivity associated with prostate-specific membrane antigen (PSMA)-targeted PET imaging, the research closely analyzed two agents: POSLUMA® (flotufolastat F 18) and piflufolastat F 18.

This multicenter study focused on men experiencing biochemical recurrence (BCR) of prostate cancer following radical prostatectomy. Among the 55 patients assessed, results indicated that the median bladder standardized uptake value (SUVmean) was significantly lower in those administered with POSLUMA compared to those receiving piflufolastat F 18. This was quantified as a median bladder SUVmean of 10.9 for POSLUMA versus 29.0 for piflufolastat F 18, showcasing a remarkable median difference of 15.1.

The implications of these results are profound. A reduction in urinary radioactivity can enhance imaging interpretation, especially in regions close to the bladder where pinpointing small cancerous lesions can often be challenging. The ability of POSLUMA to depict lower urinary radioactivity while still achieving high detection rates provides vital benefits in clinical contexts. In fact, the study reported that detection rates with POSLUMA surpassed those of piflufolastat F 18, particularly within subgroups with very low PSA levels (≤0.2 ng/mL).

Dr. Eugene Teoh, Chief Medical Officer at Blue Earth Diagnostics, highlighted the importance of these findings. He expressed that for men post-surgery for prostate cancer, rising PSA levels can evoke deep concern, particularly when conventional imaging struggles to clarify the recurrence of disease. Dr. Teoh remarked, "This head-to-head study provides essential clinical evidence that POSLUMA maintains minimal urinary radioactivity while achieving reliable detection capabilities."

Furthermore, the safety profile of both radiopharmaceuticals appeared favorable, with no significant safety concerns reported throughout the study. This is critical as the technology continues to evolve in delivering precise diagnostic imaging, particularly for those diagnosed early in their cancer journey.

In line with its findings, Blue Earth Diagnostics has strengthened its commitment to advancing molecular imaging through rigorous clinical evidence. The published results now contribute to a growing body of literature to support the application of POSLUMA as a preferred PSMA-PET imaging agent. As these findings were recently unveiled at the 2026 ASCO Genitourinary Cancers Symposium in San Francisco, they further establish Blue Earth’s leadership in the field of prostate cancer imaging and diagnostics.

Background on Prostate Cancer Recurrence and Imaging

Biochemical recurrence characterizes a scenario where PSA levels begin to rise in patients previously known to have undetectable levels, after radical surgery. It poses a challenge where imaging is essential for effective management of patients. The advancements heralded by Blue Earth Diagnostics in offering more sensitive imaging agents could also lead to earlier interventions and better-informed patient management decisions.

In conclusion, with the evidence provided by Blue Earth Diagnostics, the future of prostate cancer imaging looks promising. The results reflect a significant step forward in ensuring that patients receive the most informed care possible, highlighting the pivotal role of innovative imaging agents like POSLUMA in modern oncology diagnostics.